16 C
Wednesday, October 20, 2021

Price Target on Vertex Pharmaceuticals (NASDAQ:VRTX) Dips, Shares Gap Down

After SVB Leerink reduced the price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) from $283.00 to $267.00, the stocks of the company gapped down before Thursday’s trading. Previously, the closing price of the stock was $271.46 but the opening price was $244.00. SVB Leerink has issued a rating of ‘market perform’ on the company. The price of the last traded shares of Vertex Pharmaceuticals is $226.55, with 113,030 shares traded.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)- Price Targets, Ratings

Reports have been issued on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by various analysts. In a research report issued on Wednesday, 24th June, SunTrust Banks upgraded the price target set on the company’s stock from $285.00 to $330.00. It also issued a ‘buy’ rating.

- Advertisement -

In a research report issued on Tuesday, 14th July, the price target on Vertex Pharmaceuticals Incorporated was increased from $295.00 to $340.00 by Jefferies Financial Group along with the latter assigning a ‘buy’ rating to the former company. In a research note issued on Friday, 31st July, HC Wainwright reissued a ‘buy’ rating and lifted the price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) from $295.00 to $315.00.

In a research note issued on Friday, 18th September, a ‘hold’ rating was reissued on Vertex Vertex Pharmaceuticals by Maxim Group. The ratings of the company were cut by BidaskClub from ‘sell’ to ‘strong sell’ in a research note issued on Wednesday, 7th October.

The company’s stock has received a ‘sell’ rating from one research analyst, a ‘hold’ rating from nine analysts, a ‘buy’ rating from twenty analysts, and a ‘strong buy’ rating from one analyst. The current consensus rating of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is ‘buy’ and $294.81 is the consensus target price.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)- Other Facts

- Advertisement -

In a transaction that took place on Monday, 5th October, 10,516 shares of Vertex Pharmaceuticals were sold by director Sangeeta N. Bhatia. For $2,805,563.64 as the total value, the average selling price of the shares was $266.79. N. Bhatia is now the owner of 14,424 of the company’s shares worth $3,848,178.96, approximately.

In a transaction on Monday, 3rd August, 1,941shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were sold. The average price at which the stock was sold is $278.28, for a total value of $540,141.48.Now, post the transaction, 37,044 shares of the company’s stock worth $10,308,604.32 is owned by the executive vice president. 0.48% of the company’s stock is owned by corporate insiders.

- Advertisement -

Follow Us


Latest news